Fig. 2.

Relapse rate at 1 year, Kaplan–Meier curves, and days between fingolimod or ocrelizumab initiation and relapses for each patient. A Relapse rate at 1 year in both groups. Analysis was performed using a multivariate logistic regression adjusted for age, disease duration, sex, initial EDSS, number of relapses the year before natalizumab cessation, the time with natalizumab, washout period, and the presence of infratentorial lesions on brain MRI. B Kaplan–Meier curves of the occurrence of relapse in both groups. Analysis was performed using a Cox model. C Days between fingolimod or ocrelizumab initiation and relapses for each patient. Relapses occurred in 17/54 (31.5%) patients with fingolimod and 5/48 (10.4%) patients with ocrelizumab. HR  hazard ratio, 95% CI = 95% confidence interval. *Ocrelizumab as reference